BrainsWay pairs proprietary Deep TMS, 75% gross margins and a growing recurring lease base with strong near-term growth, but tariff, reimbursement and competitive risks make valuation discipline essential.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) is a commercial-stage medical technology company that develops and markets non-invasive neurostimulation solutions for severe psychiatric and neurological conditions [cite: 1, 2]. The cornerstone of the company’s enterprise value is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology platform [cite: 1, 3]. Unlike traditional focal neurostimulation systems, Deep TMS employs specialized electromagnetic helmet arrays designed to target deeper and broader neuronal structures within the central nervous system without requiring surgical implantation or exposing patients to systemic pharmaceutical side effects [cite: 1, 3, 4, 5].
| Operational Dimension | Corporate Detail & Strategic Exposure |
|---|---|
| Core Revenue Streams | Multi-year recurring lease agreements (~58% of top line), direct capital equipment sales, session usage/consumable fees, and annual maintenance service contracts [cite: 4, 5, 6]. |
| Geographic Mix | The United States represents the core commercial region (>80% of revenue), supplemented by direct and distributor-led expansion across Europe, Asia-Pacific, and Latin America [cite: 5, 7]. |
| Target Customers | Outpatient psychiatric private practices, multi-site behavioral health Management Services Organizations (MSOs), regional hospital networks, and academic medical research centers [cite: 1, 4, 5]. |
| Approved Indications | Treatment-Resistant Major Depressive Disorder (TRD), anxious depression, Obsessive-Compulsive Disorder (OCD), and smoking addiction [cite: 1, 5, 8]. |
BrainsWay markets integrated Deep TMS systems built around its patented H-Coil technology [cite: 1, 3, 5]. The primary commercial configurations include the H1-Coil, designed to target the dorsolateral prefrontal cortex for major depressive disorder and anxious depression, and the H7-Coil, engineered to stimulate the medial prefrontal cortex and anterior cingulate cortex for obsessive-compulsive disorder [cite: 5, 8, 9]. Complementing these hardware configurations is the commercial rollout of the SWIFT protocol—an accelerated theta-burst stimulation delivery format that compresses treatment session durations from 20 minutes down to 3 minutes [cite: 7, 10]. Beyond system placements, BrainsWay deploys an ecosystem capital allocation model by extending minority equity growth capital and convertible loans to expanding behavioral health clinic MSOs (such as Hopemark Health and Radial Health) and complementary technology developers (such as Neurolief), directly securing long-term hardware placements [cite: 2, 7, 11, 12].
The primary purchasing decisions for BrainsWay technology are made by clinical psychiatrists, behavioral health practice owners, and health system procurement committees [cite: 1, 4, 5]. The end markets served encompass a broad adult and geriatric patient population suffering from severe psychiatric conditions that have proven refractory to standard line-one and line-two oral antidepressant medications or psychotherapy regimens [cite: 1, 5, 8].
Healthcare providers select BrainsWay over traditional neurostimulation platforms based on three primary factors:
1. Deeper Stimulation Reach: BrainsWay's H-coil helmet geometries induce electrical fields up to 6 cm beneath the skull—compared to approximately 2 cm for standard figure-8 coils—enabling stimulation of sub-cortical brain structures while substantially reducing the risk of target mislocalization errors without requiring expensive, complex MRI-guided neuronavigation [cite: 3, 4, 5, 10].
2. Regulatory Indication Exclusivity: BrainsWay holds exclusive FDA clearances for Deep TMS in treating OCD and smoking addiction, providing clinics with a broader clinical addressable market [cite: 5].
3. Enhanced Practice Economics: The combination of flexible multi-year operating leases and high-throughput SWIFT protocol capability allows clinics to scale daily patient volume multi-fold under established CPT reimbursement codes ranging from $300 to $500 per session [cite: 4, 5, 7].
BrainsWay operates a dual-track commercial model designed to optimize upfront cash generation while establishing long-term recurring lease streams [cite: 5, 6]. Capital system purchases range between $100,000 and $200,000 per unit, while multi-year recurring lease structures lower capital barriers for practices in exchange for predictable, multi-year recurring receipts [cite: 4, 5]. Lease contracts typically run 2 to 3 years in duration and include ongoing software updates, hardware maintenance, and session activation credits [cite: 4, 5, 7].
A fundamental operational growth initiative is the rollout of the SWIFT protocol [cite: 7, 10]. By delivering intermittent theta-burst stimulation in 3-minute sessions, SWIFT addresses clinical throughput bottlenecks [cite: 7, 10]. This throughput acceleration doubles or triples a clinic's daily patient capacity per console, boosting practice profitability under existing reimbursement models [cite: 4, 7]. Over 57 million covered lives in the U.S. currently have reimbursement access to BrainsWay's accelerated protocols [cite: 7].
BrainsWay maintains a competitive moat built upon intellectual property, regulatory exclusivity, customer switching costs, and ecosystem alignment:
| Moat Dimension | Mechanism & Operational Advantage | Durability & Impact |
|---|---|---|
| Intellectual Property | Over 100 granted and pending international patents protecting proprietary H-coil structures, field geometries, and multi-channel coil arrays [cite: 5]. | High: Prevents direct replication of deep sub-cortical stimulation designs without infringing core claims [cite: 5]. |
| Regulatory Exclusivity | First and only FDA clearances for Deep TMS in OCD and smoking cessation [cite: 5]. | High: Competitors must fund multi-year clinical trials to obtain similar indication clearances [cite: 4, 5]. |
| Customer Switching Costs | Multi-year lease agreements, practice integration, and staff clinical training on proprietary interfaces [cite: 5, 7]. | Moderate-High: Switching platforms requires capital outlay, lease cancellation fees, and staff retraining [cite: 4, 5]. |
| Ecosystem Network | Minority equity investments in behavioral health MSOs mandate long-term system adoption in new clinic openings [cite: 2, 7, 11]. | Moderate: Locks in future system placements across growing regional clinic networks [cite: 2, 7]. |
The global market for transcranial magnetic stimulation systems was valued at $256.5 million in 2024 and is projected to reach $594.5 million by 2033, representing a compound annual growth rate (CAGR) of 9.9% [cite: 13]. When expanded to encompass the total addressable market (TAM) for depression treatment devices and interventional psychiatric technology platforms, industry forecasts project an opportunity expanding to $19.46 billion by 2033 [cite: 3]. Furthermore, management estimates an international partner market opportunity spanning over 170 million untreated patients across current distribution regions [cite: 7].
The market for clinical neurostimulation is divided between traditional standard-depth coil manufacturers and BrainsWay's Deep TMS platform [cite: 3, 4, 5]:
| Competitor Name | Hardware Technology | Market Position & Pricing Comparison | Share Trend vs. BrainsWay |
|---|---|---|---|
| Neuronetics (NeuroStar) | Standard Figure-8 Coils [cite: 4, 5] | Dominant historical U.S. unit installed base; lower upfront capital cost ($80k–$150k) but levies per-treatment cap fees [cite: 3, 4, 14]. | Losing Share: BrainsWay's multi-indication clearances and high-throughput SWIFT protocol are capturing new clinic placements [cite: 1, 5, 7]. |
| MagVenture | Standard Figure-8 & Theta-Burst Coils [cite: 4, 8] | Strong position in European outpatient clinics and academic psychiatry centers [cite: 3, 4, 14, 15]. | Holding Ground: Competes on price and protocol flexibility but lacks proprietary deep H-coil reach [cite: 4, 5]. |
| Magstim (Welcony) | Legacy Figure-8 Coils [cite: 10, 13, 14] | Established footprint in neuroscience research and hospital academic departments [cite: 10, 13, 14]. | Losing Share: Slower expansion into specialized outpatient behavioral health networks [cite: 3, 14]. |
BrainsWay is demonstrating market share gains within the outpatient psychiatry sector [cite: 1, 5]. In Q2 2026, the company shipped a record 125 Deep TMS systems (+42% YoY growth), bringing its total global installed base to approximately 1,949 systems [cite: 2, 16].
BrainsWay reported its Q2 2026 financial results on August 12, 2026, delivering top-line growth and operating margin expansion [cite: 2, 17].
| Metric | Q2 2026 Reported | Q2 2025 Prior | Year-over-Year Change | Performance vs. Consensus Expectations |
|---|---|---|---|---|
| Total Revenue | $17.11 Million [cite: 2, 16] | $12.60 Million [cite: 2, 16] | +35% [cite: 2, 16] | Beat: Consensus expected $16.54 Million (+3.4% surprise) [cite: 18]. |
| Gross Profit | $12.80 Million [cite: 16] | $9.50 Million [cite: 6] | +35% [cite: 16] | In line with elevated ~75% gross margin profile [cite: 1, 6, 17]. |
| Operating Income | $2.39 Million [cite: 2, 16] | $0.60 Million [cite: 2, 16] | +300% [cite: 2, 16] | Beat: Operating margin expanded to 14.0% from 5.0% [cite: 2, 16]. |
| Adjusted EBITDA | $3.50 Million [cite: 2, 16] | $1.50 Million [cite: 2, 16] | +141% [cite: 2, 16] | Beat: Adjusted EBITDA margin expanded to 20.0% [cite: 2, 16]. |
| GAAP EPS | $0.07 [cite: 2, 9] | $0.05 [cite: 9] | +34% [cite: 9] | Met / Beat: Reflects higher tax provisions and R&D scaling [cite: 2, 6, 9]. |
| Non-GAAP EPS | $0.14 [cite: 18] | $0.08 [cite: 7] | +75% [cite: 7, 18] | Beat: Consensus expected $0.10 (+40.0% surprise) [cite: 18]. |
| RPO Backlog | $80.40 Million [cite: 2, 16] | $62.00 Million [cite: 6] | +30% [cite: 2, 6] | High multi-year revenue visibility [cite: 2, 6, 7]. |
Driven by strong Q2 momentum, management raised its full-year 2026 financial guidance [cite: 1, 2, 16]:
* FY 2026 Total Revenue: Increased to $68.0 million–$70.0 million (up from $66.0 million–$68.0 million), representing 30% to 34% YoY growth [cite: 1, 2, 16].
* FY 2026 Adjusted EBITDA: Increased to $13.0 million–$14.0 million (up from $12.0 million–$14.0 million), representing 90% to 100% YoY growth [cite: 2, 16].
* FY 2026 Operating Margin: Raised and narrowed to 13.5%–14.0% of total revenue [cite: 2, 16].
During the Q2 2026 earnings call, CEO Hadar Levy confirmed that BrainsWay achieved its 12th consecutive quarter of profitability [cite: 7]. Management highlighted that the business is evolving from a device vendor into an interventional psychiatry platform, supported by strong collections ($6.3 million operating cash flow in Q2) and a cash balance of $62.4 million with zero debt [cite: 1, 2, 7, 16].
Following the August 12 announcement, sell-side analysts updated their projections [cite: 18, 19]: BTIG raised its price target to $20.00 per share [cite: 19], while consensus targets settled between $18.20 and $19.27 per share [cite: 18, 19]. Despite fundamental beats, BWAY stock experienced temporary selling pressure in late September 2026, pulling back toward $13.37 due to rebalancing liquidations following its removal from the S&P Global BMI Index [cite: 18, 19].
| Financial & Valuation Metric | Current Value / Ratio | Strategic Interpretation & Model Driver |
|---|---|---|
| Share Price (Baseline) | $13.37 USD [cite: 19] | Market cap of $526.9M; Enterprise Value of $464.5M [cite: 1, 2, 19]. |
| TTM Revenue | $60.70 Million USD [cite: 1] | 3-Year historical CAGR of 33.25% [cite: 17]. |
| Gross Margin Profile | 75.32% [cite: 1, 17] | Provides high incremental margin drop-through to operating profit [cite: 2, 17]. |
| Trailing P/E Ratio (GAAP) | 54.90x [cite: 1, 17, 19] | Reflects initial phase of GAAP net margin expansion [cite: 9, 17]. |
| Forward P/E Ratio (2026E) | 43.21x [cite: 17] | Compresses rapidly based on guided 90%–100% EBITDA growth [cite: 2, 16, 17]. |
| EV / Sales (TTM) | 7.80x–8.70x [cite: 1, 17] | In line with high-growth medical technology peers [cite: 1, 17, 19]. |
| EV / EBITDA (TTM) | 55.82x [cite: 17] | Reflects expanding EBITDA margins (20% in Q2 2026) [cite: 2, 17]. |
| Risk Category | Specific Operational Threat | Severity / Time Horizon | Early Warning Sign | Thesis Impact |
|---|---|---|---|---|
| Company-Specific Execution | MSO equity partner underperformance or clinic expansion delays [cite: 2, 7, 11]. | Medium / Medium-Term (1–3 Yrs) | Flat or declining quarterly system placements at partner MSOs [cite: 2, 7]. | Moderate: Impairments on non-core investments and lower utilization [cite: 2, 7]. |
| Competitive Dynamics | Rival figure-8 vendors discounting hardware or launching rival accelerated protocols [cite: 4, 8]. | High / Ongoing | Falling lease renewal rates or declining capital average selling prices [cite: 4, 5]. | High: Compresses gross margin below historical 70% threshold [cite: 1, 5, 17]. |
| Regulatory & Tariffs | 15% U.S. import tariff on Israeli goods implemented August 2025 [cite: 12]. | High / Immediate | Gross margin compression in hardware sales segment [cite: 12, 16]. | Moderate-High: Squeezes hardware margins if costs cannot be passed on [cite: 12]. |
| Reimbursement Structure | Reductions in CPT reimbursement session rates ($300–$500 baseline) [cite: 4]. | Critical / Long-Term (3–5 Yrs) | Proposed rule changes in CMS physician fee schedules [cite: 3, 18]. | Severe: Damages clinic ROI model and reduces device demand [cite: 4, 5]. |
| Macro & Capital Cost | Elevated interest rates slowing clinic capital equipment financing [cite: 4, 18]. | Medium / Short-Term (<1 Yr) | Lengthening sales cycles for outright capital system sales [cite: 4, 5]. | Low-Moderate: Drives customer shifts toward lease structures [cite: 5, 6]. |
The 5-year valuation model evaluates the trajectory of BrainsWay from FY 2026 through FY 2031, using a current baseline share price of $13.37 USD [cite: 19], 40.21 million basic shares outstanding [cite: 17, 19], and an initial FY 2026 revenue guidance midpoint of $69.0 million USD [cite: 2, 16].
Total Returns: Implied 5-year total return of +52.8%; Annualized return (CAGR) of +8.8%.
High Case Scenario (25% Probability Weight):
Total Returns: Implied 5-year total return of +212.0%; Annualized return (CAGR) of +25.5%.
Low Case Scenario (20% Probability Weight):
| Metric / Year | Base Year (2026E) | Year 1 (2027E) | Year 2 (2028E) | Year 3 (2029E) | Year 4 (2030E) | Year 5 (2031E) |
|---|---|---|---|---|---|---|
| Base Case Price (USD) | $13.37 [cite: 19] | $14.50 | $15.80 | $17.20 | $18.75 | $20.43 |
| High Case Price (USD) | $13.37 [cite: 19] | $16.80 | $21.20 | $26.50 | $33.10 | $41.72 |
| Low Case Price (USD) | $13.37 [cite: 19] | $11.20 | $9.50 | $7.80 | $6.30 | $5.04 |
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case | $157.87 Million USD | 22.0% Net Margin / $0.817 EPS | 25.0x P/E | $13.37 USD [cite: 19] | $20.43 USD | +52.8% | +8.8% | 55% |
| High Case | $210.57 Million USD | 26.0% Net Margin / $1.304 EPS | 32.0x P/E | $13.37 USD [cite: 19] | $41.72 USD | +212.0% | +25.5% | 25% |
| Low Case | $101.38 Million USD | 12.0% Net Margin / $0.280 EPS | 18.0x P/E | $13.37 USD [cite: 19] | $5.04 USD | -62.3% | -17.8% | 20% |
| Weighted Target | -- | -- | -- | $13.37 USD [cite: 19] | $22.68 USD | +69.6% | +11.1% | 100% |
EXPANDING HIGH-MARGIN PLATFORM
| Evaluation Metric | Score (1 - 10 Scale) | Detailed Analytical Narrative |
|---|---|---|
| Management Alignment | 8 / 10 | CEO Hadar Levy brings over a decade of executive experience at BrainsWay (CFO, COO, CEO since Feb 2023) [cite: 20, 21]. Executive compensation is tied to top-line revenue targets and Adjusted EBITDA expansion milestones [cite: 2, 21]. |
| Revenue Quality | 9 / 10 | High recurring revenue proportion driven by multi-year leases (~58% of top line) and a $80.4 million RPO backlog, providing multi-quarter visibility [cite: 2, 5, 6]. |
| Market Position | 8 / 10 | Holds exclusive FDA clearances in OCD and smoking addiction while capturing market share in MDD from legacy figure-8 coil providers [cite: 1, 5, 8]. |
| Growth Outlook | 8 / 10 | Guided FY 2026 revenue growth of 30% to 34% supported by SWIFT protocol adoption and MSO network deployments [cite: 2, 7, 16]. |
| Financial Health | 9 / 10 | Strong balance sheet with $62.4 million in cash, zero debt, and positive operating cash flows ($6.3 million in Q2 2026) [cite: 1, 2, 7, 16]. |
| Business Viability | 8 / 10 | Core business viability is supported by over 100 patents, durable clinical trial data, and established CPT reimbursement coverage [cite: 4, 5]. |
| Capital Allocation | 7 / 10 | Strategic minority investments in MSO partners secure direct device placements, though allocating capital to non-core entity loans introduces investment risk [cite: 2, 7, 11, 12]. |
| Analyst Sentiment | 8 / 10 | Wall Street sentiment remains positive, with consensus price targets ($18.20–$19.27) implying potential upside relative to current levels [cite: 18, 19]. |
| Profitability | 8 / 10 | High gross profit margins (~75.3%) drive operating leverage, supporting guided Adjusted EBITDA margins of 19%–20% for FY 2026 [cite: 1, 2, 16, 17]. |
| Track Record | 7 / 10 | Management has executed a turnaround over the past three fiscal years, delivering 12 consecutive quarters of profitability [cite: 1, 7, 9, 20]. |
| OVERALL BLENDED SCORE | 8.0 / 10 | STRONG OPERATIONAL FUNDAMENTALS |
DISRUPTIVE MEDTECH LEADER
BrainsWay Ltd. represents an interventional psychiatry platform thesis [cite: 7]. The company’s core valuation drivers combine proprietary H-coil technology, high gross profit margins (~75.3%), and an order backlog ($80.4 million RPO) that supports forward revenue visibility [cite: 1, 2, 5, 17]. Key catalysts supporting operational momentum include:
* Accelerated adoption of the 3-minute SWIFT protocol, expanding practice capacity and provider returns [cite: 7, 10].
* Capital deployment into minority MSO equity positions, locking in long-term system demand across growing psychiatric clinic networks [cite: 2, 7, 11].
* Potential expansion into secondary indications such as PTSD and early-stage Alzheimer’s combination therapies [cite: 7, 9, 22].
These operational growth catalysts are balanced by execution risks, including potential gross margin headwinds from a 15% U.S. import tariff on Israeli goods and competitive discounting from traditional figure-8 TMS manufacturers [cite: 4, 12]. Nevertheless, BrainsWay's debt-free balance sheet ($62.4 million cash) and 12-quarter track record of profitability provide flexibility to navigate macroeconomic volatility while scaling its interventional platform footprint [cite: 1, 2, 7].
HIGH-GROWTH INTERVENTIONAL PLATFORM
BrainsWay’s stock traded near $13.37 USD in late September 2026 [cite: 19], below its 50-day simple moving average of $14.91 and its 200-day simple moving average of $14.81 [cite: 18]. The recent share price pullback from 52-week highs ($17.40) was triggered by forced index fund liquidations following BWAY's deletion from the S&P Global BMI Index, rather than operational or financial degradation [cite: 1, 17, 18]. With technical indicators showing oversold conditions and underlying fundamentals showing 35% Q2 revenue growth [cite: 2, 18], the short-term outlook points toward potential technical consolidation around current support levels ahead of the next quarterly earnings catalyst [cite: 18, 19].
SHORT-TERM TECHNICAL PULLBACK
View BrainsWay Ltd. (BWAY) stock page
Loading the interactive version of this report…